UW Today

FDA-approved immune-modulating drug unexpectedly benefits mice with fatal mitochondrial defect

Rapamycin, an anti-rejection drug for organ transplant patients, has now been shown to increases survival in and delayed symptoms of Leigh’s syndrome. The drug appears to cause a metabolic switch that bypasses the mitochondrial deficiency.